ONCOPRO LIQUID BIOPSY Test
Cost: AED 38610.0
Symptoms, Diagnosis, and Test Details
The ONCOPRO LIQUID BIOPSY Test is a non-invasive diagnostic test used to detect cancer by analyzing circulating tumor DNA (ctDNA) present in a patient’s blood sample. The test is used to monitor the progression of cancer, identify potential drug resistance, and determine the best treatment options for the patient.
The ONCOPRO LIQUID BIOPSY Test consists of a 73 Gene Panel with MSI, including genes such as ABL1, AKT1, ALK, APC, AR, ARID1A, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTCF, CTNNB1, DNMT3A, EGFR, EP300, EPHA3, EPHA5, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GATA3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KEAP1, KIT, KRAS, LIFR, MAP2K1, MAP3K1, MET, MLH1, MPL, MTOR, NAV3, NFE2L2, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PIK3R1, PTCH1, PTEN, PTPN11, RB1, RUNX1, SETD2, SMAD2, SMAD4, SMARCA4, SMARCB1, SMO, SRC, STK11, TP53, VHL, ROS1, BRCA2, and BRCA1.
The ONCOPRO LIQUID BIOPSY Test is a highly sensitive and specific test that can detect even small amounts of ctDNA, making it a valuable tool for early cancer detection and personalized cancer treatment. The test is minimally invasive and can be performed on an outpatient basis, making it convenient for patients.
Test Information
- Price: AED 38610.0
- Sample Condition: 20 mL whole blood in 2 Streck tubes available from LPL. Ship immediately at 18-22°C. DO NOT REFRIGERATE OR FREEZE.
- Report Delivery: Sample daily by 9 am; Report 35 working days
- Method: Next Generation Sequencing
- Test Type: Cancer
- Doctor: Oncologist
- Test Department: Molecular Diagnostics
- Pre Test Information: Duly filled OncoPro Liquid Biopsy Clinical Information Form (Form 32) is mandatory.
The ONCOPRO LIQUID BIOPSY Test is a promising new technology that has the potential to revolutionize cancer diagnosis and treatment.
Test Name | ONCOPRO LIQUID BIOPSY Test |
---|---|
Components | 73 Gene Panel with MSI: *ABL1, *AKT1, *ALK, *APC, *AR, *ARID1A, *ATM, *BRAF, *CDH1, *CDKN2A, *CSF1R, *CTCF, *CTNNB1, *DNMT3A, *EGFR, *EP300, *EPHA3, *EPHA5, *ERBB2, *ERBB4, *EZH2, *FBXW7, *FGFR1, *FGFR2, *FGFR3, *FLT3, *GATA3, *GNA11, *GNAQ, *GNAS, *HNF1A, *HRAS, *IDH1, *IDH2, *JAK2, *JAK3, *KDR, *KEAP1, *KIT, *KRAS, *LIFR, *MAP2K1, *MAP3K1, *MET, *MLH1, *MPL, *MTOR, *NAV3, *NFE2L2, *NOTCH1, *NPM1, *NRAS, *PDGFRA, *PIK3CA, *PIK3R1, *PTCH1, *PTEN, *PTPN11, *RB1, *RUNX1, *SETD2, *SMAD2, *SMAD4, *SMARCA4, *SMARCB1, *SMO, *SRC, *STK11, *TP53, *VHL, *ROS1, *BRCA2, *BRCA1 |
Price | 38610.0 AED |
Sample Condition | 20 mLwhole bloodin 2 Streck tubes available from LPL. Ship immediately at 18\u0192??22?\u00f8C. DO NOT REFRIGERATE OR FREEZE. Duly filled OncoPro Liquid Biopsy Clinical Information Form (Form 32)is mandatory. |
Report Delivery | Sample Daily by 9 am; Report 35 Working days |
Method | Next Generation Sequencing |
Test type | Cancer |
Doctor | Oncologist |
Test Department: | MOLECULAR DIAGNOSTICS |
Pre Test Information | Duly filled OncoPro Liquid Biopsy Clinical Information Form (Form 32)is mandatory. |
Test Details | ONCOPRO Liquid Biopsy Test is a non-invasive diagnostic test used to detect cancer by analyzing circulating tumor DNA (ctDNA) present in a patient’s blood sample. The test is used to monitor the progression of cancer, identify potential drug resistance, and determine the best treatment options for the patient. The ONCOPRO Liquid Biopsy Test is a highly sensitive and specific test that can detect even small amounts of ctDNA, making it a valuable tool for early cancer detection and personalized cancer treatment. The test is minimally invasive and can be performed on an outpatient basis, making it convenient for patients. The ONCOPRO Liquid Biopsy Test is a promising new technology that has the potential to revolutionize cancer diagnosis and treatment. |